CAN-2409 Market Summary

Key Factors Driving CAN-2409 Growth

1. Positive Phase III results in localized prostate cancer provide the strongest growth catalyst: The pivotal Phase III trial enrolled 745 patients and met its primary endpoint, with CAN-2409 + radiotherapy reducing the risk of disease recurrence or death by 30% (HR 0.70; p=0.0155) versus radiotherapy alone. Median DFS was not reached with CAN-2409 versus 86.1 months in the control arm. At extended follow-up of 58 months, prostate-cancer-specific DFS remained significantly improved by 39% (HR 0.61; p=0.0031). These results provide the clinical foundation for the planned BLA and potential launch.

2. Potentially differentiated treatment for a large localized prostate-cancer population: CAN-2409 is designed to deliver the HSV-thymidine kinase (HSV-tk) gene directly into tumors. With valacyclovir, the expressed HSV-tk converts the prodrug into toxic nucleotide analogs, promoting tumor-cell death and release of tumor antigens, while the adenoviral vector stimulates local inflammation and immune activation. This multimodal mechanism could complement radiotherapy rather than simply replacing it.

3. Large addressable US opportunity: Candel estimates that more than 100,000 men are diagnosed with localized prostate cancer annually in the US and more than 50,000 currently receive radiotherapy. The company estimates a potential >$10 billion US addressable market for aglatimagene in localized prostate cancer. Importantly, this is a company estimate based on external analysis, not a market-research-firm sales forecast; therefore, it should be interpreted as an addressable-market estimate rather than expected revenue.

4. Potential to reduce recurrence and downstream salvage treatment: The clinical benefit extends beyond the primary DFS endpoint. In the 58-month follow-up, CAN-2409 showed favorable trends in time to biochemical failure, time to metastasis and time to salvage anticancer treatment. Among the intermediate-risk subgroup, representing 85% of the trial population, prostate-cancer-specific DFS improved by 41% (HR 0.59; p=0.0034), while an exploratory analysis showed a 90% reduction in time-to-metastasis risk. If confirmed with longer follow-up, reducing recurrence and delaying subsequent treatments could strengthen payer and physician adoption.

5. Regulatory advantages and potential first-in-class positioning: The FDA has granted CAN-2409 both Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for localized prostate cancer, while the Phase III trial was conducted under a Special Protocol Assessment (SPA) agreed with the FDA. Candel is in ongoing discussions with the FDA and plans to submit the BLA in Q4 2026. If approved, Candel believes aglatimagene could become the first new first-line treatment for localized prostate cancer in more than 20 years, potentially giving it a differentiated commercial position.

CAN-2409 Recent Developments

• In August 2026, Candel Therapeutics, a clinical-stage immuno-oncology company, is advancing its lead candidate CAN-2409 toward a biologics license application (BLA) submission expected in the fourth quarter, with management highlighting "meaningful execution" toward the filing. The company is targeting its first commercial product launch in 2027, positioning regulatory progress as a key catalyst for the stock.
• In September 2025, Candel Therapeutics, a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, presented subgroup analyses focused on the radiation regimen from the Company’s positive Phase III clinical trial of CAN-2409 (aglatimagene besadenovec) in patients with intermediate-to-high-risk localized prostate cancer at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO).

“CAN-2409 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of CAN-2409 for potential indication like Non-small cell lung cancer, Prostate cancer, Pancreatic cancer, Triple negative breast cancer, Malignant pleural effusion, and Ovarian cancer in the 7MM. A detailed picture of CAN-2409’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the CAN-2409 for potential indications. The CAN-2409 market report provides insights about CAN-2409’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current CAN-2409 performance, future market assessments inclusive of the CAN-2409 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of CAN-2409 sales forecasts, along with factors driving its market.

CAN-2409 Drug Summary

CAN-2409 is an investigational gene-mediated cytotoxic immunotherapy developed by Candel Therapeutics for the treatment of solid tumors, particularly localized prostate cancer. It is a replication-defective adenoviral vector engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene directly into tumors; when administered with the prodrug valacyclovir, the expressed thymidine kinase converts the prodrug into cytotoxic metabolites that damage tumor-cell DNA and induce immunogenic cell death, releasing tumor antigens and stimulating a broader anti-tumor immune response. CAN-2409 is administered by direct intratumoral/intraprostatic injection, followed by oral valacyclovir, and has been investigated in prostate cancer, non-small cell lung cancer and glioblastoma. In a Phase 3 trial involving 745 patients with intermediate- or high-risk localized prostate cancer, CAN-2409 plus valacyclovir and standard radiotherapy significantly improved disease-free survival versus placebo plus valacyclovir and radiotherapy, with a hazard ratio of 0.70 (p=0.016); median DFS was not reached in the CAN-2409 group versus 86.1 months for placebo. The positive results support its potential as a novel immunotherapy approach that complements radiotherapy while potentially reducing disease recurrence. The report provides CAN-2409’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the CAN-2409 Market Report

The report provides insights into:

• A comprehensive product overview including the CAN-2409 MoA, description, dosage and administration, research and development activities in potential indication like Non-small cell lung cancer, Prostate cancer, Pancreatic cancer, Triple negative breast cancer, Malignant pleural effusion, and Ovarian cancer.
• Elaborated details on CAN-2409 regulatory milestones and other development activities have been provided in CAN-2409 market report.
• The report also highlights CAN-2409‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The CAN-2409 market report also covers the patents information, generic entry and impact on cost cut.
• The CAN-2409 market report contains current and forecasted CAN-2409 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The CAN-2409 market report also features the SWOT analysis with analyst views for CAN-2409 in potential indications.

Methodology

The CAN-2409 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CAN-2409 Analytical Perspective by DelveInsight

• In-depth CAN-2409 Market Assessment

This CAN-2409 sales market forecast report provides a detailed market assessment of CAN-2409 for potential indication like Non-small cell lung cancer, Prostate cancer, Pancreatic cancer, Triple negative breast cancer, Malignant pleural effusion, and Ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted CAN-2409 sales data uptil 2034.

• CAN-2409 Clinical Assessment

The CAN-2409 market report provides the clinical trials information of CAN-2409 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

CAN-2409 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

CAN-2409 Market Potential & Revenue Forecast

• Projected market size for the CAN-2409 and its key indications
• Estimated CAN-2409 sales potential (CAN-2409 peak sales forecasts)
• CAN-2409 Pricing strategies and reimbursement landscape

CAN-2409 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• CAN-2409 Market positioning compared to existing treatments
• CAN-2409 Strengths & weaknesses relative to competitors

CAN-2409 Regulatory & Commercial Milestones

• CAN-2409 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

CAN-2409 Clinical Differentiation

• CAN-2409 Efficacy & safety advantages over existing drugs
• CAN-2409 Unique selling points

CAN-2409 Market Report Highlights

• In the coming years, the CAN-2409 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The CAN-2409 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CAN-2409’s dominance.
• Other emerging products for Non-small cell lung cancer, Prostate cancer, Pancreatic cancer, Triple negative breast cancer, Malignant pleural effusion, and Ovarian cancer are expected to give tough market competition to CAN-2409 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CAN-2409 in potential indications.
• Analyse CAN-2409 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted CAN-2409 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of CAN-2409 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of CAN-2409? How strong is CAN-2409’s clinical and commercial performance?
• What is CAN-2409’s clinical trial status in each individual indications such as Non-small cell lung cancer, Prostate cancer, Pancreatic cancer, Triple negative breast cancer, Malignant pleural effusion, and Ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CAN-2409 Manufacturers?
• What are the key designations that have been granted to CAN-2409 for potential indications? How are they going to impact CAN-2409’s penetration in various geographies?
• What is the current and forecasted CAN-2409 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of CAN-2409 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to CAN-2409 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is CAN-2409? What is the duration of therapy and what are the geographical variations in cost per patient?